Trials / Enrolling By Invitation
Enrolling By InvitationNCT07474051
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
Persistence Evaluation and Response Study for Immunotherapy Safety Tracking of Participants Who Receive an AvenCell CAR-T Cell Therapy
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 178 (estimated)
- Sponsor
- AvenCell Therapeutics, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or RevCAR platforms.
Detailed description
To assess the incidence and severity of delayed serious adverse events (SAEs) possibly related to AVC-CAR-T cell therapy and AEs of special interest (AESIs), including secondary malignancies, neurologic disorders, rheumatologic or other autoimmune disorders, newly diagnosed serious hematologic disorders, severe infections, as well as pregnancy and newborn health complications where observed.
Conditions
- B-cell Lymphoma
- Chronic Lymphocytic Leukemia
- Hematologic Malignancy
- AML (Acute Myelogenous Leukemia)
- Prostate Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UniCAR02-T (IMP) With Targeting Module TM123 | No investigational product will be administered |
| BIOLOGICAL | UniCAR02-T-pPSMA | No investigational product will be administered |
| BIOLOGICAL | Allo-RevCAR01- T with Targeting Module R-TM123 | No investigational product will be administered |
| BIOLOGICAL | Allo-QuadCAR01-T | No investigational product will be administered |
Timeline
- Start date
- 2026-01-29
- Primary completion
- 2040-11-30
- Completion
- 2041-01-30
- First posted
- 2026-03-16
- Last updated
- 2026-03-16
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT07474051. Inclusion in this directory is not an endorsement.